Secretory phospholipase A2 (SPLA2) as a prognostic and diagnostic marker for cardiovascular disease

摘要

The present invention relates to a method for determining an increased risk of mortality or of a cardiac and/or vascular event in a patient, comprising: - determining the sPLA2 activity of said patient, - comparing said activity to a predetermined value, a higher sPLA2 activity of said patient as compared to said predetermined value being indicative of an increased risk of mortality or of a cardiac and/or vascular event.